Renascience Inc. (4889.T)
Tokyo · JPY · Healthcare · Medical Devices
¥983 (+1.44%) as of
Key statistics
- Market cap
- 13.54B
- EPS (TTM)
- -24.09
- Dividend yield
- 0.00%
- 52-week range
- 931.00 – 2,228.00
- Beta
- 1.71
- Revenue (TTM)
- 68M
- Profit margin
- 0.00%
- Volume
- 113.00k
About Renascience Inc.
Renascience Inc. develops and sells pharmaceuticals, medical devices, and artificial intelligence (AI)-powered programmed medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence-based medical solutions; pancreatic cancer; anti-aging and longevity oral drugs (senolytics); topical medications for male pattern baldness and age-related hair loss; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Sendai, Japan.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Sendai, Japan
- Employees
- 3
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.